Renew Medical Center is at the forefront of treating diabetic kidney disease with their innovative MicroDose treatment. Unlike traditional drug-based therapies, MicroDose administers insulin as a hormone, directly targeting the underlying cause of diabetes - metabolic failure. By replicating natural physiological processes, MicroDose effectively reduces insulin resistance, which facilitates the absorption of blood sugar into cells, where it's converted into energy. This groundbreaking approach has shown promising results in improving the management of diabetic kidney disease.
By using the MicroDose treatment, the body can produce more cellular energy, which may aid in the growth, repair, and regeneration of impaired tissues and organs. This approach not only helps stabilize complications related to diabetes and other metabolic disorders but, in numerous instances, has also been proven to reverse them.
The MicroDose system (MDS) treatment approach uses the "pulse-rest" intervals of insulin production to reactivate alternative insulin-signaling pathways, which can improve kidney function and potentially reverse kidney tissue damage.
This treatment option, developed in the USA specifically designed to restore the natural insulin cycle seen in healthy individuals, which can help improve kidney function, prevent proteinuria loss, and reduce further damage.
The primary factors contributing to kidney disease are Diabetes and Hypertension. The MicroDose system serves as an optimal solution for managing both conditions.
With MDS treatment insulin sensitivity is improved, the following benefits may be observed for individuals with kidney disease:
MDS helps in lowering blood pressure levels, reducing the strain on the blood vessels in the kidneys and reducing the risk of kidney damage and proteinuria. By improving insulin sensitivity and addressing insulin resistance, this therapy may also have additional benefits in managing metabolic disorders that can contribute to kidney disease, such as obesity and type 2 diabetes.
Typical Care Plan for Patients with Kidney Disease.
At our facility, we understand that each patient's degree of insulin resistance and efficiency of carbohydrate metabolism is unique. That's why we start with a consultation to determine medical necessity and establish a physician-directed, individualized care plan.
The care plan we develop for each patient typically includes an "Induction Phase" of two infusions per week, reducing to one per week for around 90 days. This is followed by a "Maintenance Phase" focused on finding the optimal balance between metabolism and insulin sensitivity, with a goal of extending the time between treatments for as long as possible.
Patients with conditions such as Kidney disease, High blood pressure, Type 2 Diabetes, Prediabetes, and Nondiabetic conditions usually begin their treatment with three-hour infusions during the Induction Phase. As the treatment progresses, the infusions are typically reduced to two hours, allowing them to maintain optimized metabolism and insulin sensitivity for four to six weeks between treatments.
Patients seeking MDS treatment can contact us to schedule an appointment with our physicians.
